Clinical Trial

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2026 (before its estimated June 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
Protocol Amendment History 1 change
notable Primary completion pushed: 2025-09-29 -> 2026-06-14 2026-06-04
Trial Details
NCT Number NCT06433219
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Ovarian Cancer
Enrollment 63 participants
Start Date 2024-10-30
Primary Completion 2026-06-14 (estimated)
Study Completion 2026-06-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-03